ImmunityBio, Inc. (IBRX) saw its stock price soar by 5.61% during intraday trading on Friday, reflecting significant investor optimism.
The surge appears to be driven by positive analyst coverage, with H.C. Wainwright reiterating a Buy rating on the company and setting a price target of $15.00. This analyst endorsement has likely contributed to increased buying interest in the stock.